A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
Most of biologics manufacturer are concentrated in US, Germany,UK and other developed countries. But in biosimilars industry the situation is different, manufacturer in developing countries play a very important role.
The research shows that the growth of biologics industry may be slow but high profits during the period of patent may be attractive to newcomers.

Market Analysis and Insights: Global Biologics and Biosimilars Market
The global Biologics and Biosimilars market size is projected to reach US$ 471580 million by 2026, from US$ 299000 million in 2020, at a CAGR of 7.9% during 2021-2026.

Global Biologics and Biosimilars Scope and Market Size
The global Biologics and Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biologics and Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Biologics and Biosimilars market is segmented into
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others

Segment by Application, the Biologics and Biosimilars market is segmented into
Tumor
Diabetes
Cardiovascular
Hemophilia
Others

The Biologics and Biosimilars market is analysed and market size information is provided by regions (countries). Segment by Application, the Biologics and Biosimilars market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Biologics and Biosimilars Market Share Analysis
Biologics and Biosimilars market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Biologics and Biosimilars business, the date to enter into the Biologics and Biosimilars market, Biologics and Biosimilars product introduction, recent developments, etc.

The major vendors covered:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee